The puzzle of overactive bladder: controversies, inconsistencies, and insights
- 27 June 2006
- journal article
- review article
- Published by Springer Nature in International Urogynecology Journal
- Vol. 17 (6), 650-658
- https://doi.org/10.1007/s00192-005-0032-3
Abstract
Overactive bladder (OAB) affects millions of individuals and may severely impair the quality of life of those affected. The contribution of human behavior to manifestations of this symptom complex remains poorly understood. Continued evolution of our understanding of the pathophysiology of OAB has identified contributory mechanisms, which in turn may open new therapeutic avenues. Recent improvements in drug delivery systems represent advances in the management of OAB. However, more complete symptom control with greater tolerability is desirable; this awaits the development of agents specific for newly emerging and as yet unidentified pathophysiologic pathways. Importantly, as understanding of outcomes assessment in OAB matures, refined assessments of disease severity, response to intervention, and patient preference should be possible.This publication has 101 references indexed in Scilit:
- Lower Urinary Tract Symptoms and Pelvic Floor Muscle Exercise Adherence After 15 YearsObstetrics & Gynecology, 2005
- Long-Term Open-Label Solifenacin Treatment Associated with Persistence with Therapy in Patients with Overactive Bladder SyndromeEuropean Urology, 2005
- An investigation of dose titration with darifenacin, an M3‐selective receptor antagonistBJU International, 2005
- INTERVENTIONS AND OUTCOMES. WHAT IS IMPORTANT (AND WHAT IS NOT)?Journal of Urology, 2004
- TROSPIUM CHLORIDE IMPROVES OVERACTIVE BLADDER SYMPTOMS: A MULTICENTER PHASE III TRIALJournal of Urology, 2004
- Randomized, double‐blind placebo‐ and tolterodine‐controlled trial of the once‐daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladderBJU International, 2004
- Transdermal OxybutyninDrugs & Aging, 2003
- Treatment of Overactive Bladder with Once-daily Extended-release Tolterodine or Oxybutynin: The Antimuscarinic Clinical Effectiveness Trial (ACET)Current Medical Research and Opinion, 2002
- P2X RECEPTORS AND THEIR ROLE IN FEMALE IDIOPATHIC DETRUSOR INSTABILITYJournal of Urology, 2002
- Bladder training for urinary incontinence in adultsPublished by Wiley ,1999